AI Article Synopsis
- Researchers studied the effects of glucagon-like peptide-1 receptor agonists (GLP1-RA) versus Dipeptidyl peptidase-4 inhibitors (DPP4i) in U.S. veterans aged 35 and older with chronic kidney disease (CKD) and type 2 diabetes (T2D) from 2006 to 2021.
- They aimed to see how these treatments affected healthcare usage, mortality rates, and cardiovascular events.
- Results showed that GLP1-RA use led to lower healthcare utilization and all-cause mortality rates without a significant difference in cardiovascular events after a follow-up period of about 2.2 years.
Article Abstract
Treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) may attenuate kidney disease progression and cardiovascular events but their real-world impact on healthcare utilization and mortality in this population are not well-defined. Here, we emulate a clinical trial that compares outcomes following initiation of GLP1-RA vs Dipeptidyl peptidase-4 inhibitors (DPP4i), as active comparators, in U.S. veterans aged 35 years of older with moderate to advanced CKD during fiscal years 2006 to 2021. Primary outcome was rate of acute healthcare utilization. Secondary outcomes were all-cause mortality and a composite of acute cardiovascular events. After propensity score matching (16,076 pairs) and 2.2 years mean follow-up duration, use of GLP1-RA in patients with moderate to advanced CKD was associated with lower annual rate of acute healthcare utilization and all-cause mortality. There was no significant difference in acute cardiovascular events.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621321 | PMC |
| http://dx.doi.org/10.1038/s41467-024-54009-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!